Silexion Therapeutics Corp filed a Form 8-K on November 9, 2026, announcing a prospective 1-for-24 reverse share split of its ordinary shares, effective after the close of market on November 10, 2026.
Aura Biosciences, Inc. submitted its quarterly report on Form 10-Q covering the period ended September 30, 2026, disclosing operational risks, development status of its sole product candidate bel-sar, and a share count of 104,074,302 shares of common stock outstanding as of November 4, 2026.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) submitted its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing share count, pipeline status, and financial statement structure for the third quarter of its fiscal year.
FACT II Acquisition Corp. filed a Form 8-K on November 9, 2026, disclosing plans to enter into non-redemption agreements with unaffiliated investors ahead of an extraordinary general meeting scheduled for November 17, 2026, and reporting a trust account redemption price of approximately $10.81 per …
Powerfleet, Inc. filed a Form 8-K with the SEC on November 9, 2026, furnishing a press release and slide presentation covering financial results for the fiscal quarter ended September 30, 2026.
Zura Bio Limited filed a Form 8-K on November 9, 2026, disclosing a clinical update on its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa.
Aura Biosciences, Inc. filed a Current Report on Form 8-K with the SEC on November 9, 2026, announcing its financial results for the quarter ended September 30, 2026, and an updated corporate presentation.
Affiliated Managers Group, Inc. filed a Form 8-K on November 9, 2026, disclosing its financial and operating results for the quarter ended September 30, 2026, and announcing a quarterly common stock dividend of $0.01 per share.
Akamai Technologies, Inc. filed an 8-K on November 9, 2026, disclosing a November 5, 2026 amendment to its Credit Agreement and announcing an intended private offering of $2.2 billion in Convertible Senior Notes.
Scott C. Sherman, SVP, CLO and CHRO of Sally Beauty Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing five derivative security acquisitions dated November 4, 2026, covering newly awarded restricted stock units and certified performance stock units.